The sensitivity of TCCSUP (PIK3CAE545K; grade IV), but not RT112 (grade I-II), cells to 3-BrPA (Fig. 5f-g) corroborates drug’s proficiency to specifically target bladder cancer cells carrying oncogenic H-Ras and/or aberrant PI3K/Akt signaling. This evidence concerns the gene AKT1 and urinary bladder carcinoma.